Description
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
This trial is available at multiple Sutter Locations. Please contact one of the following about Study ECOG E4512
San Francisco: ClinicalResearch@sutterhealth.org
Palo Alto/Santa Cruz: Tanya Pozniansky pozniat@sutterhealth.org
PAMF/Fremont: Tanya Pozniansky pozniat@sutterhealth.org
East Bay: Vivian Leong, RN Leongv@sutterhealth.org
Sacramento: Kirsten Babski babskik@sutterhealth.org
Modesto: Adrienne Palos PalosA@sutterhealth.org
Solano-Vallejo Cancer Center: Stephanie Gonzales gonzals1@sutterhealth.org
San Mateo:Stephanie Casal CasalSL@sutterhealth.org andBonnie Chan ChanBW@sutterhealth.org
Santa Rosa:Patricia Grinnell GrinneP@sutterhealth.org
View study details on ClinicalTrials.govPrincipal Investigator
Recruitment Status
Active, Recruiting
Start Date
February 01, 2019
Related Studies
SEER Lung Cancer
Investigator: Tze-Ming Chen, M.D., FCCP
The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity
Investigator: Jiang Li, Ph.D., MPH